Table 3.

Odds ratio (OR) and 95% confidence interval (CI) of clinical status and GAS5 rs145204276 genotypic frequencies in 579 patients with prostate cancer.

Variable	Genotypic frequencies
rs145204276	ins/ins (N=263)	ins/del + del/del (N=316)	OR (95% CI)	p value
PSA at diagnosis (ng/mL)
≤ 10	148 (56.3%)	161 (50.9%)	1.00	p=0.201
> 10	115 (43.7%)	155 (49.1%)	1.239 (0.892-1.721)
Pathologic Gleason grade group
1+2+3	216 (82.1%)	268 (84.8%)	1.00	p=0.386
4+5	47 (17.9%)	48 (15.2%)	0.823 (0.530-1.278)
Clinical T stage
1+2	223 (84.8%)	278 (88.0%)	1.00	p=0.264
3+4	40 (15.2%)	38 (12.0%)	0.762 (0.473-1.229)
Pathologic T stage
2	140 (53.2%)	166 (52.5%)	1.00	p=0.867
3+4	123 (46.8%)	150 (47.5%)	1.029 (0.741-1.427)
Pathologic N stage
N0	234 (89.0%)	296 (93.7%)	1.00	p=0.043*
N1	29 (11.0%)	20 (6.3%)	0.545 (0.301-0.988)
Seminal vesicle invasion
No	194 (73.8%)	258 (81.6%)	1.00	p=0.022*
Yes	69 (26.2%)	58 (18.4%)	0.632 (0.426-0.939)
Perineural invasion
No	63 (24.0%)	92 (29.1%)	1.00	p=0.163
Yes	200 (76.0%)	224 (70.9%)	0.767 (0.528-1.114)
Lymphovascular invasion
No	211 (80.2%)	271 (85.8%)	1.00	p=0.076
Yes	52 (19.8%)	45 (14.2%)	0.674 (0.435-1.044)
D'Amico classification
Low risk/ Intermediate risk	129 (49.0%)	151 (47.8%)	1.00	p=0.762
High risk	134 (51.0%)	165 (52.2%)	1.052 (0.758-1.459)

The ORs with analyzed by their 95% CIs were estimated by logistic regression models. * p value < 0.05 as statistically significant.